Published in AIDS Weekly, April 9th, 2001
Writing in the journal Pharmacoeconomics, J.J. Caro and colleagues described the results of their study comparing triple therapies with either efavirenz or indinavir combined with zidovudine and lamivudine.
They found that efavirenz-based regimens not only were significantly to produce positive results, but also to save substantial amounts of money as well.
Efavirenz-based triple therapy produced five-year...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.